Dipyridamole
- Generic Name
- Dipyridamole
- Brand Names
- Aggrenox, Persantine
- Drug Type
- Small Molecule
- Chemical Formula
- C24H40N8O4
- CAS Number
- 58-32-2
- Unique Ingredient Identifier
- 64ALC7F90C
- Background
A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752)
- Indication
For as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.
- Associated Conditions
- Coronary Artery Disease (CAD), Postoperative Thromboembolism, Stroke, Thrombosis, Transient Ischemic Attack
- Associated Therapies
- Anti-platelet Therapy
Enhancement of Postocclusive Reactive Hyperaemia by Dipyridamole
- First Posted Date
- 2005-12-22
- Last Posted Date
- 2008-03-28
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 12
- Registration Number
- NCT00268554
- Locations
- 🇳🇱
Radboud university Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
Methotrexate Plus Dipyridamole in Treating Patients With Advanced Ovarian Cancer
- Conditions
- First Posted Date
- 2004-08-30
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Ottawa Regional Cancer Centre
- Registration Number
- NCT00002487
- Locations
- 🇨🇦
Ottawa Regional Cancer Centre - Civic Campus, Ottawa, Ontario, Canada
🇨🇦Ottawa Regional Cancer Center - General Division, Ottawa, Ontario, Canada
S9700 Combination Chemotherapy in Treating Patients With Stage II or Stage III Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-01-03
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 54
- Registration Number
- NCT00003018
- Locations
- 🇺🇸
MBCCOP - University of South Alabama, Mobile, Alabama, United States
🇺🇸Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
Recurrent Carotid Stenosis
- Conditions
- First Posted Date
- 1999-10-28
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- Emory University
- Registration Number
- NCT00000527
Platelet Drug Trial in Coronary Disease Progression
- Conditions
Platelet-Inhibitor Drug Trial in Coronary Angioplasty
- Conditions
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.